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Abstract
Background: During the influenza season of 2007-08, oseltamivir-resistant influenza A (H1N1) viruses emerged in 
several countries in Europe, North America, and Asia. Despite substantial prevalence of oseltamivir-resistant viruses, few 
data are available on the clinical profile of subjects infected with these viruses. Objectives: to describe the first 
oseltamivir-resistant (H1N1) influenza virus pandemic 2009 from the Eastern Mediterranean Region including Yemen 
and to determine the evidence by clinical presentation of children infected with these oseltamivir - resistant viruses.
Methodology: History, physical examination and laboratory investigations including Complete Blood Count, chest x-
ray, blood cultures, CSF examination, LFTs, RFTs, blood for sugar, H1N1 test and oseltamivir resistance test.
Results: Nasal swabs indicated positivity on both H1N1 test and the RNP gene (Human R Nase P gene that serves as 
internal positive control for Human RNA. Both clinical specimens presented the mutation S31N in the M2 gene 
associated with resistance to adamantanes and H274Y in NA gene associated with resistance to oseltamivir. This was 
the first diagnosed case of resistance to oseltamivir in Yemen and also it is the first reported case of oseltamivir 
resistance virus in the Eastern Mediterranean Region.
Conclusion: The pattern of resistance found in the oseltamivir resistant isolate collected from Yemen is the same as 
has been reported elsewhere in other WHO regions. Clinical description and outcomes are not different from what is 
described elsewhere.
Introduction
During the influenza season of 2007-08, oseltamivir-
resistant influenza A (H1N1) viruses emerged in several
countries in Europe, North America, and Asia. Despite
substantial prevalence of oseltamivir-resistant viruses,
few data are available on the clinical profile of subjects
infected with these viruses [1]. In this paper we describe
the first oseltamivir-resistant pandemic (H1N1) 2009
influenza virus from the Eastern Mediterranean Region
including Yemen and determine the evidence of clinical
presentation of children infected with these viruses
regarding the occurrence of oseltamivir-resistance.
Case report
3 years old female patient, known case of congenital heart
disease with pulmonary hypertension and cerebral palsy
was admitted to the hospital on 7th October 2009 with
h i g h  g r a d e  o f  f e v e r ,  c o u g h ,  s o r e  t h r o a t ,  d i f f i c u l t y  i n
breathing and body aches. Clinical examination: patient
was semiconscious, disoriented and severe pale. Heart:
Pan-systolic-murmur. Chest: bronchial breathing and
crepitation on the right lung. Abdomen: soft, mild
hepatomegaly. On the day of the hospitalization diag-
nosed as severe acute respiratory infection and admitted
to the intensive care unit (ICU) under ventilator. Lab-
Investigation was done (CBC, chest x-ray, blood culture,
CSF examination, LFTs, RFTs, blood for sugar and blood
culture). The results of lab-test were within normal range
except lymphocytosis. It gives a suggestion that the infec-
tion could be viral and may due to H1N1.
On 9th October 2009 nasal swab was taken for H1N1
test and introduce oseltamivir (Tamiflu) to the list of
t r e a t m e n t.  O n  t h e  s a m e  da y  t h e  r e s u l t  ( R T - PCR )  c o n -
firmed the diagnosis: H1N1 complicated severe acute
respiratory infection; the patient spent more than 10 days
in the ICU without clinical improvement. On review,
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repeat chest x-ray showed features of slight improvement.
Second nasal swab was taken for H1N1 test. The result
was still positive with high titration. The worsening pic-
ture suggested that the case could be resistant to oselta-
mivir. On 19th October 2009 two throat swabs were taken
and send to the EMRO for more confirmation and testing
for resistance.
On 23rd  October 2009 test results from NAMRU-3
indicated that both specimens were positive for pan-
demic H1N1 and positive for the RNP gene (Human R
Nase P gene that serves as internal positive control for
Human RNA). Both clinical specimens presented the
mutation S31N in the M2 gene associated with resistance
to adamantanes. This mutation is present in all pandemic
H1N1 viruses. Both clinical specimens contained the
mutation H274Y in NA gene associated with resistance to
oseltamivir. It was the first case of resistance to oseltami-
vir in Y emen and also it is the first case of oseltamivir
resistance virus in the Eastern Mediterranean Region [2].
Drug treatments
During hospitalization (from 7th  to 31 October 2009)
patient was under several drugs including antibiotics
such as (cephalosporin, makrolides, and clindamycine).
Oseltamivir start on 9th October and stopped on 19th
October 2009.
On 31 October 2009, we stopped all treatment except
multivitamins and nutrition. The patient (1st November
2009) clinically improved with no fever and difficulty in
breathing
Discussion
Pandemic influenza A (H1N1) was first identified in
Yemen on 17th June 2009. By the end of February, the
number of lab-confirmed H1N1 cases had reached 629
including 17th deaths associated with a case fatality rate
3%. Since the beginning of current influenza pandemic, a
total of 40 cases of oseltamivir-resistant pandemic
(H1N1) 2009 virus including this one from Yemen [3].
The dramatic rise of oseltamivir resistance in the H1N1
serotype in the 2007/2008 season3, and the fixing of
H274Y in the 2008/2009 season have raised concerns
regarding individuals at risk for seasonal influenza, as
well as development of similar resistance in the H5N1
serotype3. Previously, oseltamivir resistance produced
changes in H1N1 and H3N2 at multiple positions in
treated patients. In contrast, the recently reported resis-
tance involved patients who had not recently taken osel-
tamivir [4,5].
Moreover, the resistance was limited to the H1N1
which had acquired H274Y1, 2. H274Y jumped from
clade2C (Hong Kong/2562/2006-like) to clade 1 (New
Caledonia/20/1999-like) to clade 2B (Brisbane/59/2007-
like) which included multiple introductions. Sub-clades
that had acquired key changes on the neuraminidase and
hemagglutinin genes expanded and fixed of H274Y on
H1N1. These changes led to the spread of adamantane
resistance on clade 2C outside of Asia, followed by the
spread of oseltamivir resistance in 2007/2008 and the fix-
ing of H274Y in 2008/2009.
The aggregation of key polymorphisms onto different
genetic backgrounds supports a mechanism of homolo-
gous recombination between co-circulating influenza
sub-clades, and provides a rationale for the prediction of
vaccine targets and emergence of antiviral resistance
[4,5].
The pattern of resistance found in the oseltamivir resis-
tant isolate collected from Yemen is the same as has been
reported elsewhere in other WHO Regions2. Prior stud-
ies of oseltamivir resistance in Japan5 were linked to sub-
optimal dosing and resistance was found in both current
influenza A subtypes, H1N1 and H3N2, and included, but
was not limited to H274Y. Prior studies also supported a
fitness penalty for the acquisition of H274Y, which pre-
dicted that the change would be limited to patients
receiving oseltamivir [4,5].
Moreover, this isolate, and others collected over the
summer in Hong Kong have a clade 2C HA and M2
which has H274Y in NA (both clade 2B and clade C) as
well as S31N on M2, signaling additional exchanges of
polymorphisms6 leading to the emergence of H1N1
which is resistant to oseltamivir and the adamantanes [4-
6]. All these studies are going with the result of our case
report.
The global experience with drug resistant pandemic
influenza virus has shown that the risk of resistance is
considered higher in patients who have prolonged illness
(particularly those with severally compromised or sup-
pressed immune system)and who have received antiviral
treatment for an extended duration and still test positive
for the virus2, this is an agreement with our case report;
Moreover there is a strong need to monitor vigilantly for
changes in transmissibility or pathogenicity of the pan-
demic (H1N1) 2009 influenza virus which may not be evi-
dent on a case-by case basis. Because of that any changes
in the transmissibility and drug resistance of the virus will
have pro-found implication on the clinical case manage-
ment.
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